{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tatebe H"],"funding":["Hokkaido University","AMED"],"pagination":["i8-i15"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10278876"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["64(Supplement_1)"],"pubmed_abstract":["This study presents the first data of a Japanese nationwide multi-institutional cohort and compares them with the findings of systematic literature reviews on radiation therapies and inoperable stage III non-small cell lung cancer (NSCLC) conducted by the Lung Cancer Working Group in the Particle Beam Therapy (PBT) Committee and Subcommittee at Japanese Society for Radiation Oncology. The Lung Cancer Working Group extracted eight reports and compared their data with those of the PBT registry from May 2016 to June 2018. All the analyzed 75 patients aged ≤80 years underwent proton therapy (PT) with concurrent chemotherapy for inoperable stage III NSCLC. The median follow-up period of the surviving patients was 39.5 (range, 1.6-55.6) months. The 2- and 3-year overall survival (OS) and progres"],"journal":["Journal of radiation research"],"pubmed_title":["Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study."],"pmcid":["PMC10278876"],"funding_grant_id":["JP16lm0103004"],"pubmed_authors":["Nakayama H","Satouchi M","Waki T","Taguchi H","Nakamura M","Tatebe H","Iwata H","Ogino T","Akimoto T","Harada H","Mori K","Murakami M","Aoyama H"],"additional_accession":[]},"is_claimable":false,"name":"Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study.","description":"This study presents the first data of a Japanese nationwide multi-institutional cohort and compares them with the findings of systematic literature reviews on radiation therapies and inoperable stage III non-small cell lung cancer (NSCLC) conducted by the Lung Cancer Working Group in the Particle Beam Therapy (PBT) Committee and Subcommittee at Japanese Society for Radiation Oncology. The Lung Cancer Working Group extracted eight reports and compared their data with those of the PBT registry from May 2016 to June 2018. All the analyzed 75 patients aged ≤80 years underwent proton therapy (PT) with concurrent chemotherapy for inoperable stage III NSCLC. The median follow-up period of the surviving patients was 39.5 (range, 1.6-55.6) months. The 2- and 3-year overall survival (OS) and progres","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-22T02:04:42.988Z","creation":"2025-04-05T20:13:01.019Z"},"accession":"S-EPMC10278876","cross_references":{"pubmed":["37137157"],"doi":["10.1093/jrr/rrad017"]}}